Renal Aplasia in Humans Is Associated with RET Mutations

American Journal of Human Genetics

Volumn 82, Issue 2, 2008, Pages 344-351

  Skinner, Michael A ^a   Safford, Shawn D ^b   Reeves, Justin G ^c   Jackson, Margaret E ^c   Freemerman, Alex J ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PROTEIN RET; RET PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; FETUS; GDNF GENE; GENE; GENE MUTATION; GFRA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY AGENESIS; KIDNEY DEVELOPMENT; KIDNEY DYSPLASIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RET GENE; STILLBIRTH; COMPARATIVE STUDY; CONGENITAL MALFORMATION; DNA SEQUENCE; GENETICS; KIDNEY; KIDNEY DISEASE; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PLASMID; SITE DIRECTED MUTAGENESIS;

ANIMALIA;

BASE SEQUENCE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; KIDNEY; KIDNEY DISEASES; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHORYLATION; PLASMIDS; PROTO-ONCOGENE PROTEINS C-RET; SEQUENCE ANALYSIS, DNA;

EID: 40749161593     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajhg.2007.10.008     Document Type: Article

References (54)

1. Wilson R.D., and Baird P.A. Renal agenesis in British Columbia. Am. J. Med. Genet. 21 (1985) 153-169
2. Roodhooft A.M., Birnholz J.C., and Holmes L.B. Familial nature of congenital absence and severe dysgenesis of both kidneys. N. Engl. J. Med. 319 (1984) 1341-1344
3. Bates C.M. Kidney development: regulatory molecules crucial to both mice and men. Mol. Genet. Metab. 71 (2000) 391-396
4. Yu J., McMahon A.P., and Valerius M.T. Recent genetic studies of mouse kidney development. Curr. Opin. Genet. Dev. 14 (2004) 550-557
5. Schuchardt A., D'Agati V., Larsson-Blomberg L., Constantini F., and Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367 (1994) 380-383
6. Pichel J.G., Shen L., Hui S.Z., Granholm A.-C., Drago J., Grinberg A., Lee E.J., Huang S.P., Saarma M., Hoffer B.J., et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382 (1996) 73-76
7. Cacalano G., Farinas I., Wang L.-C., Hagler K., Forgie A., Moore M., Armanini M., Phillips H., Ryan A.M., Reichardt L.F., et al. GFRa1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 21 (1998) 53-62
8. Lore F., Di Cairano G., and Talidis F. Unilateral renal agenesis in a family with medullary thyroid carcinoma. N. Engl. J. Med. 342 (2000) 1218-1219
9. Lore F., Talidis F., Di Cairano G., and Renieri A. Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. J. Intern. Med. 250 (2001) 37-42
10. Korkko J., Annunen S., Pihlajamaa T., Prockop D.J., and Ala-Kokko L. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc. Natl. Acad. Sci. USA 95 (1998) 1681-1685
11. Larsen L.A., Christiansen M., Vuust J., and Andersen P.S. Recent developments in high-throughput mutation screening. Pharmacogenomics 2 (2001) 387-399
12. Iwamoto T., Taniguchi M., Asai N., Ohkusu K., Nakashima I., and Takahashi M. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 8 (1993) 1087-1091
13. Tansey M.G., Baloh R.H., Milbrandt J., and Johnson Jr. E.M. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25 (2000) 611-623
14. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., and Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 (1990) 557-563
15. Klugbauer S., Lengfelder E., Demidchik E.P., and Rabes H.M. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11 (1995) 2459-2467
16. Bounacer A., Wicker R., Caillou B., Cailleux A.F., Sarasin A., Schlumberger M., and Suarez H.G. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15 (1997) 1263-1273
17. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., and Wells Jr. S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2 (1993) 851-856
18. Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
19. Carlson K.M., Dou S., Chi D., Scavarda N., Toshima T., Jackson C.E., Wells Jr. S.A., Goodfellow P.J., and Donis-Keller H. Single missense mutation in the tyrosine kinase domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA 91 (1994) 1579-1583
20. Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagon T., Luo Y., Pasini B., Hoppener J.W.M., van Amstel H.K.P., Romeo G., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
21. Eng C., Smith D.P., Mulligan L.M., Nagal M.A., Healey C.S., Ponder M.A., Gardner E., Scheumann G.F.W., Jackson C.E., Tunacliffe A., and Ponder B.A.J. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. 3 (1994) 237-241
22. Santoro M., Rosati R., Grieco M., Berlingieri M.T., D'Amato G.L., de Franciscis V., and Fusco A. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5 (1990) 1595-1598
23. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H., and Di Fiore P.P. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 (1995) 381-383
24. Romeo R., Ronchetto P., Luo Y., Barone V., Serl M., Ceccherini I., Pasini B., Bocclardl R., Lerone M., Kaalainen H., and Marucciello G. Point mutations affecting the tyrosine domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367 (1994) 377-378
25. Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., Nihoul-Fekete C., Ponder B.A.J., and Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367 (1994) 378-380
26. Pelet A., Attie T., Goulet O., Eng C., Ponder B.A.J., Munnich A., and Lyonnet S. De novo mutations of the RET proto-oncogenein Hirschsprung's disease. Lancet 344 (1994) 1769-1770
27. Edery P., Pelet A., Mulligan L.M., Abel L., Attie T., Dow E., Bonneau D., David A., Flintoff W., Jan D., et al. Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus. J. Med. Genet. 31 (1994) 602-606
28. Pelet A., Geneste O., Edery P., Pasini A., Chappuis S., Atti T., Munnich A., Lenoir G., Lyonnet S., and Billaud M. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J. Clin. Invest. 101 (1998) 1415-1423
29. Attie-Bitach T., Abitbol M., Gerard M., Delezoide A.L., Auge J., Pelet A., Amiel J., Pachnis V., Munnich A., Lyonnet S., and Vekemans M. Expression of the RET proto-oncogene in human embryos. Am. J. Med. Genet. 80 (1998) 481-486
30. Pachnis V., Mankoo B., and Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119 (1993) 1005-1017
31. Sinnassamy P., Yazbeck S., Brochu P., and O'Regan S. Renal anomalies and agenesis associated with total intestinal aganglionosis. Int. J. Pediatr. Nephrol. 7 (1986) 1-2
32. Santos H., Mateus J., and Leal M.J. Hirschsprung disease associated with polydactyly, unilateral renal agenesis, hypertelorism, and congenital deafness: a new autosomal recessive syndrome. J. Med. Genet. 25 (1988) 204-205
33. Wong A., Bogni S., Kotka P., de Graaff E., D'Agati V., Costantini F., and Pachnis V. Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol. Cell. Biol. 25 (2005) 9661-9673
34. Bolk S., Pelet A., Hofstra R.M., Angrist M., Salomon R., Croaker D., Buys C.H., Lyonnet S., and Chakravarti A. A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc. Natl. Acad. Sci. USA 97 (2000) 268-273
35. Fitze G., Cramer J., Ziegler A., Schierz M., Schreiber M., Kuhlisch E., Roesner D., and Schackert H.K. Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet 359 (2002) 1200-1205
36. Miyauchi A., Matsuzuka F., Hirai K., Yokozawa T., Kobayashi K., Ito Y., Nakano K., Kuma K., Futami H., and Yamaguchi K. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J. Surg. 26 (2002) 1023-1028
37. Iwashita T., Kurokawa K., Qiao S., Murakami H., Asai N., Kawai K., Hashimoto M., Watanabe T., Ichihara M., and Takahashi M. Functional analysis of RET with Hirschsprung mutations affecting its kinase domain. Gastroenterology 121 (2001) 24-33
38. Ishiguro Y., Iwashita T., Murakami H., Asai N., Iida K., Goto H., Hayakawa T., and Takahashi M. The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain. Endocrinology 140 (1999) 3992-3998
39. Iwashita T., Murakami H., Asai N., and Takahashi M. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum. Mol. Genet. 5 (1996) 1577-1580
40. Cosma M.P., Cardone M., Carlomagno F., and Colantuoni V. Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol. Cell. Biol. 18 (1998) 3321-3329
41. Kjaer S., and Ibanez C.F. Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET. Hum. Mol. Genet. 12 (2003) 2133-2144
42. Takahashi M., Iwashita T., Santoro M., Lyonnet S., Lenoir G.M., and Billaud M. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?. Hum. Mutat. 13 (1999) 331-336
43. Carniti C., Belluco S., Riccardi E., Cranston A.N., Mondellini P., Ponder B.A., Scanziani E., Pierotti M.A., and Bongarzone I. The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease. Am. J. Pathol. 168 (2006) 1262-1275
44. Yin L., Puliti A., Bonora E., Evangelisti C., Conti V., Tong W.M., Medard J.J., Lavoue M.F., Forey N., Wang L.C., et al. C620R mutation of the murine ret proto-oncogene: loss of function effect in homozygotes and possible gain of function effect in heterozygotes. Int. J. Cancer 121 (2007) 292-300
45. Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J., Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum. Mol. Genet. 3 (1994) 2163-2167
46. Arighi E., Popsueva A., Degl'Innocenti D., Borrello M.G., Carniti C., Perala N.M., Pierotti M.A., and Sariola H. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol. Endocrinol. 18 (2004) 1004-1017
47. Pasini B., Borrello M.G., Greco A., Bongarzone I., Luo Y., Mondellini P., Alberti L., Miranda C., Arighi E., Bocciardi R., et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat. Genet. 10 (1995) 35-40
48. Gabriel S.B., Salomon R., Pelet A., Angrist M., Amiel J., Fornage M., Attie-Bitach T., Olson J.M., Hofstra R., Buys C., et al. Segregation at three loci explains familial and population risk in Hirschsprung disease. Nat. Genet. 31 (2002) 89-93
49. Skinner M.A., Kalyanaraman S., Safford S.D., Heuckeroth R.O., Tourtellotte W., Goyeau D., Goodfellow P., Milbrandt J.D., and Freemerman A. A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-deficient mice. Am. J. Pathol. 166 (2005) 265-274
50. Angrist M., Bolk S., Halushka M., Lapchak P.A., and Chakravarti A. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat. Genet. 14 (1996) 341-344
51. Salomon R., Attie T., Pelet A., Bidaud C., Eng C., Amiel J., Sarnacki S., Goulet O., Ricour C., Nihoul-Fekete C., et al. Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease. Nat. Genet. 14 (1996) 345-347
52. Ivanchuk S.M., Myers S.M., Eng C., and Mulligan L.M. De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease. Hum. Mol. Genet. 5 (1996) 2023-2026
53. Vockley J., Rinaldo P., Bennett M.J., Matern D., and Vladutiu G.D. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol. Genet. Metab. 71 (2000) 10-18
54. Anders J., Kjar S., and Ibanez C.F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J. Biol. Chem. 276 (2001) 35808-35817